Shiwei Zhou1, Guangyu Yang2, Min Zhang2, Michael Pienta3, Carol E Chenoweth4, Francis D Pagani3, Keith D Aaronson5, Michael D Fetters6, P Paul Chandanabhumma6, Lourdes Cabrera3, Hechuan Hou3, Preeti N Malani4, Donald S Likosky3. 1. Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Mich. Electronic address: shzh@med.umich.edu. 2. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Mich. 3. Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Mich. 4. Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Mich. 5. Division of Cardiovascular Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Mich. 6. Department of Family Medicine, Michigan Medicine, Ann Arbor, Mich.
Abstract
OBJECTIVE: Although infections are common after left ventricular assist device implantation, the relationship between timing and type of first infection with regard to mortality is less well understood. METHODS: The Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support patients receiving a primary left ventricular assist device from April 2012 to May 2017 were included. The primary exposure was defined 3 ways: any infection, timing of first infection (early: ≤90 days; intermediate: 91-180 days; late: >180 days), and type (ventricular assist device specific, ventricular assist device related, non-ventricular assist device). The association between first infection and all-cause mortality was estimated using Cox regression. RESULTS: The cohort included 12,957 patients at 166 centers (destination therapy: 47.4%, bridge-to-transplant: 41.2%). First infections were most often non-ventricular assist device (54.2%). Rates of first infection were highest in the early interval (10.7/100 person-months). Patients with any infection had a significantly higher adjusted hazard of death (hazard ratio, 2.63; 2.46-2.86). First infection in the intermediate interval was associated with the largest increase in adjusted hazard of death (hazard ratio, 3.26; 2.82-3.78), followed by late (hazard ratio, 3.13; 2.77-3.53) and early intervals (hazard ratio, 2.37; 2.16-2.60). Ventricular assist device-related infections were associated with the largest increase in hazard of death (hazard ratio, 3.02; 2.69-3.40), followed by ventricular assist device specific (hazard ratio, 2.92; 2.57-3.32) and non-ventricular assist device (hazard ratio, 2.42; 2.20-2.65). CONCLUSIONS: Relative to those without infection, patients with any postimplantation infection had an increased risk of death. Ventricular assist device-related infections and infections occurring in the intermediate interval were associated with the largest increase in risk of death. After left ventricular assist device implantation, infection prevention strategies should target non-ventricular assist device infections in the first 90 days, then shift to surveillance/prevention of driveline infections after 90 days.
OBJECTIVE: Although infections are common after left ventricular assist device implantation, the relationship between timing and type of first infection with regard to mortality is less well understood. METHODS: The Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support patients receiving a primary left ventricular assist device from April 2012 to May 2017 were included. The primary exposure was defined 3 ways: any infection, timing of first infection (early: ≤90 days; intermediate: 91-180 days; late: >180 days), and type (ventricular assist device specific, ventricular assist device related, non-ventricular assist device). The association between first infection and all-cause mortality was estimated using Cox regression. RESULTS: The cohort included 12,957 patients at 166 centers (destination therapy: 47.4%, bridge-to-transplant: 41.2%). First infections were most often non-ventricular assist device (54.2%). Rates of first infection were highest in the early interval (10.7/100 person-months). Patients with any infection had a significantly higher adjusted hazard of death (hazard ratio, 2.63; 2.46-2.86). First infection in the intermediate interval was associated with the largest increase in adjusted hazard of death (hazard ratio, 3.26; 2.82-3.78), followed by late (hazard ratio, 3.13; 2.77-3.53) and early intervals (hazard ratio, 2.37; 2.16-2.60). Ventricular assist device-related infections were associated with the largest increase in hazard of death (hazard ratio, 3.02; 2.69-3.40), followed by ventricular assist device specific (hazard ratio, 2.92; 2.57-3.32) and non-ventricular assist device (hazard ratio, 2.42; 2.20-2.65). CONCLUSIONS: Relative to those without infection, patients with any postimplantation infection had an increased risk of death. Ventricular assist device-related infections and infections occurring in the intermediate interval were associated with the largest increase in risk of death. After left ventricular assist device implantation, infection prevention strategies should target non-ventricular assist device infections in the first 90 days, then shift to surveillance/prevention of driveline infections after 90 days.
Authors: Mandeep R Mehra; Nir Uriel; Yoshifumi Naka; Joseph C Cleveland; Melana Yuzefpolskaya; Christopher T Salerno; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Steven W Hutchins; John Ransom; Gregory A Ewald; Akinobu Itoh; Nirav Y Raval; Scott C Silvestry; Rebecca Cogswell; Ranjit John; Arvind Bhimaraj; Brian A Bruckner; Brian D Lowes; John Y Um; Valluvan Jeevanandam; Gabriel Sayer; Abeel A Mangi; Ezequiel J Molina; Farooq Sheikh; Keith Aaronson; Francis D Pagani; William G Cotts; Antone J Tatooles; Ashok Babu; Don Chomsky; Jason N Katz; Paul B Tessmann; David Dean; Arun Krishnamoorthy; Joyce Chuang; Ia Topuria; Poornima Sood; Daniel J Goldstein Journal: N Engl J Med Date: 2019-03-17 Impact factor: 91.245
Authors: William L Holman; James K Kirklin; David C Naftel; Robert L Kormos; Patricia Desvign-Nickens; Margarita T Camacho; Deborah D Ascheim Journal: J Thorac Cardiovasc Surg Date: 2010-04-03 Impact factor: 5.209
Authors: Chetan B Patel; Laura Blue; Barbara Cagliostro; Stephen H Bailey; John W Entwistle; Ranjit John; Vinay Thohan; Joseph C Cleveland; Daniel J Goldstein; Nir Uriel; Xiaolu Su; Sami I Somo; Poornima Sood; Mandeep R Mehra Journal: J Heart Lung Transplant Date: 2020-03-20 Impact factor: 10.247
Authors: Mark R Hemmila; Anne H Cain-Nielsen; Jill L Jakubus; Judy N Mikhail; Justin B Dimick Journal: JAMA Surg Date: 2018-08-01 Impact factor: 14.766
Authors: S M Gordon; S K Schmitt; M Jacobs; N M Smedira; M Goormastic; M K Banbury; M Yeager; J Serkey; K Hoercher; P M McCarthy Journal: Ann Thorac Surg Date: 2001-09 Impact factor: 4.330
Authors: Jennifer A Frontera; Randall Starling; Sung-Min Cho; Amy S Nowacki; Ken Uchino; M Shazam Hussain; Maria Mountis; Nader Moazami Journal: J Heart Lung Transplant Date: 2016-12-23 Impact factor: 10.247
Authors: Andreas Zierer; Spencer J Melby; Rochus K Voeller; Tracey J Guthrie; Gregory A Ewald; Kim Shelton; Michael K Pasque; Marc R Moon; Ralph J Damiano; Nader Moazami Journal: Ann Thorac Surg Date: 2007-08 Impact factor: 4.330
Authors: Saima Aslam; Rongbing Xie; Jennifer Cowger; James K Kirklin; Vivian H Chu; Stephan Schueler; Theo de By; Kate Gould; Orla Morrissey; Lars H Lund; Stanley Martin; Daniel Goldstein; Margaret Hannan Journal: J Heart Lung Transplant Date: 2018-04-25 Impact factor: 10.247
Authors: Min Zhang; P Paul Chandanabhumma; Michael D Fetters; Francis D Pagani; Preeti N Malani; John M Hollingsworth; Russell J Funk; Keith D Aaronson; Robert L Kormos; Carol E Chenoweth; Supriya Shore; Tessa M F Watt; Lourdes Cabrera; Donald S Likosky Journal: JMIR Res Protoc Date: 2020-01-07